Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04486625 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetic Study of Aztreonam-Avibactam in Severe Renal Impairment
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT04486625 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 11 participants.
The verdict
NCT04486625, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
This Phase 1 study is being conducted to evaluate the effect of severe renal impairment on the PK, safety and tolerability of Aztreonam-Avibactam. Results from this study along with previous renal impairment data from each of the Aztreonam-Avibactam components will be used to confirm the proposed dosing adjustment in severe renal impairment which was based on modelling/simulation.
Interventions
- DRUG Aztreonam-Avibactam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2020-08-10 |
| Est. Completion | 2021-10-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04486625
The ClinicalTrials.gov registry entry for NCT04486625 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Aztreonam-Avibactam is the first listed.
NCT04486625 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04486625 about?
NCT04486625 is a clinical study titled "Pharmacokinetic Study of Aztreonam-Avibactam in Severe Renal Impairment". This Phase 1 study is being conducted to evaluate the effect of severe renal impairment on the PK, safety and tolerability of Aztreonam-Avibactam. Results from this study along with previous renal impairment data from each of the Aztreonam-Avibactam components will be used to confirm the proposed do...
What is the current status of trial NCT04486625?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2020-08-10. Estimated completion is 2021-10-18.
What interventions are being tested in trial NCT04486625?
The interventions under investigation include: Aztreonam-Avibactam (DRUG).
Who is sponsoring clinical trial NCT04486625?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.